Heparin-induced thrombocytopenia: An update

Thrombosis Journal

Volumn 3, Issue , 2005, Pages

  Franchini, Massimo ^a,b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b OSPEDALE POLICLINICO   (Italy)

Author keywords

Heparin; Platelets; Thrombosis

Indexed keywords

ARGATROBAN; DANAPAROID; DEXTRAN 70; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4;

ARTERY THROMBOSIS; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FREQUENCY ANALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE COUNT; VEIN THROMBOSIS;

EID: 27644553521     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-3-14     Document Type: Review

References (53)

1. Chong BH: Heparin-induced thrombocytopenia. J Thromb Haemost 2003, 1:1471-1478.
2. Jang I-K, Hursting HJ: When heparins promote thrombosis. Review of heparin-induced thrombocytopenia. Circulation 2005, 111:2671-2683.
3. Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121:535-555.
4. Warkentin TE: Heparin-induced thrombocytopenia. Diagnosis and management. Circulation 2004, 110:e454-458.
5. Cines DB, Bussel JB, McMillan RB, Zehnder JL: Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2004, 390-406.
6. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):311S-337S.
7. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG: Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30:1765-1771.
8. Warkentin TE: An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004, 30:273-283.
9. Rice L: Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 2004, 164:1961-1964.
10. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
11. Kelton JG: Heparin-induced thrombocytopenia: an overview. Blood Rev 2002, 16:77-80.
12. Baglin TP: Heparin-induced thrombocytopenia/thrombosis syndrome (HIT): diagnosis and treatment. Platelets 1997, 8:72-82.
13. Comunale ME, van Cott EM: Heparin-induced thrombocytopenia. Int Anesthesiol Clin 2004, 42:27-43.
14. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S: Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997, 56:12-16.
15. Girolami B, Prandoni P, Stefani PM, et al: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003, 101:2955-2959.
16. Lindhoff-Last E, Eichler P, Stein M, et al: A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000, 97:387-393.
17. Locke CFS, Dooley J, Gerber J: Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in nonsurgical patients are low and similar. Thrombosis J 2005, 3:4.
18. Reilly RF: The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003, 16:54-60.
19. Arepally G, Cines DB: Pathogenesis of heparin-induced thrombocytopenia and thrombosis. Autoimmun Rev 2002, 1:125-132.
20. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994, 83:3232-3239.
21. Cines DB, Tomaski A, Tannenbaum S: Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987, 316:581-589.
22. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994, 93: 81-88.
23. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 334:1286-1292.
24. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001, 135:502-506.
25. Bell WR: Heparin-associated thrombocytopenia and thrombosis. J Lab Clin Med 1988, 111:600-605.
26. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101:502-507.
27. Greinacher A: Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost 1995, 21:106-116.
28. Warkentin TE: Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999, 82:439-447.
29. Meyer-Lindenberg A, Quenzel EM, Bierhoff E, Wolff H, Schindler E, Biniek R: Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Eur Neurol 1997, 37:191-192.
30. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG: Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993, 84:322-328.
31. Warkentin TE: Heparin-induced skin lesions. Br J Haematol 1996, 92:494-497.
32. Klein HG, Bell WR: Disseminated intravascular coagulation during heparin therapy. Ann Intern Med 1974, 80:477-481.
33. Alving BM: How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003, 101:31-37.
34. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629-635.
35. Chong BH: Diagnosis, treatment and pathophysiology of immune-mediated thrombocytopenia. Crit Rev Oncol Hematol 1995, 20:271-296.
36. Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70:554-561.
37. Greinacher A, Janssens U, Berg G, et al: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999, 100:587-593.
38. Greinacher A, Volpel H, Janssens U, et al: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999, 99:73-80.
39. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M: Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000, 96:846-851.
40. Lewis BE, Wallis DE, Berkowitz SD, for the ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
41. Chong BH, Gallus AS, Cade JF, for the Australian HIT Study Group: Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 2001, 86:1170-1175.
42. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127:804-812.
43. Ortel TL, Gockerman JP, Califf RM, et al: Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost 1992, 67:292-296.
44. Ortel TL, Chong BH: New treatment options for heparin-induced thrombocytopenia. Sem Hematol 1998, 35(Suppl. 5):26-34.
45. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A: Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004, 104:3072-3077.
46. Farner B, Eichler P, Kroll H, Greinacher A: A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001, 85:950-957.
47. Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004, 91:361-369.
48. Gosselin RC, Dager WE, King JH, et al: Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004, 121:593-599.
49. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK: Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001, 85:435-440.
50. Hursting MJ, Lewis BE, Macfarlane DE: Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005, 11:279-287.
51. Savi P, Chong BH, Greinacher A, et al: Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractioned heparin. Blood 2005, 105:139-144.
52. Harenberg J, Jorg I, Fenyvesi T: Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2005, 89:1017-1018.
53. Kuo KHM, Kovacs MJ: Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005, 93:999-100.